Form 4: Cidara Therapeutics CEO Reports Stock Transactions

Cidara Therapeutics' President and CEO, Jeffrey Stein, reported the withholding of shares for taxes and acquisition of shares through an employee stock purchase plan.

Summary

• Jeffrey Stein, President & CEO and Director of Cidara Therapeutics, Inc. (CDTX), reported changes in his beneficial ownership.
• 2,285 shares of Common Stock were disposed of on December 10, 2025, at a price of $219.6 per share, primarily for tax withholding related to RSU vesting.
• Following this transaction, Stein directly owns 56,199 shares of Common Stock.
• This direct ownership includes 600 shares acquired through the Issuer's Employee Stock Purchase Plan (ESPP), with 200 shares purchased on each of November 20, 2024, May 20, 2025, and November 20, 2025.
• Stein also holds indirect beneficial ownership of 2,100 shares through his son and 24,580 shares through a trust.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including shares withheld for tax obligations and shares acquired through an employee stock purchase plan. These are standard events and do not indicate significant positive or negative sentiment regarding the company's performance or outlook.

Positives

• Continued participation in the company's Employee Stock Purchase Plan (ESPP), acquiring 600 shares over three purchase dates, indicates ongoing commitment and belief in the company's value.
• The majority of the reported shares disposed were for tax withholding purposes, a common and expected event following RSU vesting, rather than a discretionary sale.

Negatives

• 2,285 shares of Common Stock were disposed of, reducing direct beneficial ownership, although this was for tax obligations.

Future Outlook

NA

Industry Context

This Form 4 filing details routine insider transactions for a biotechnology company executive. Such filings are common across all industries and provide transparency into executive stock ownership changes, often related to compensation events like RSU vesting and participation in employee stock plans.

Stakeholder Impact

• Shareholders: Provides transparency into executive stock ownership and compensation practices, confirming that a key executive continues to hold a significant stake in the company, including through an ESPP.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Jeffrey Stein, Form 4, Insider Transaction, Stock Ownership, RSU Vesting, Employee Stock Purchase Plan, ESPP, Beneficial Ownership